Updated: CytoSorbents to Present at the Jefferies Global Healthcare Conference in London
CTSOPRINCETON, N.J., Nov. 17, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that management will present and participate in...
Citius Oncology, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update
CTSOLYMPHIR commercial availability planned for the fourth quarter of 2025 $12.5 million in gross financings raised during the quarter by Citius Pharmaceuticals, with an additional $9 million raised by Citius Oncology in July 2025, to facilitate LYMPHIR pre-launch initiatives and drive...
CytoSorbents Reports Second Quarter 2025 Financial Results and Provides Business Update
CTSOPRINCETON, N.J., Aug. 7, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported financial results for the second quarter ended June 30,...
CytoSorbents Presents Real-World Analysis At EuroPCR 2025 Showing Reduction In Severe Bleeding And Transfusion Needs In CABG Patients On Blood Thinner, Ticagrelor, With CytoSorbents Therapy
CTSOD. Boral Capital Maintains Buy on CytoSorbents, Maintains $10 Price Target
CTSOHC Wainwright & Co. Reiterates Neutral on CytoSorbents, Maintains $1 Price Target
CTSOCytoSorbents's Earnings: A Preview
CTSODemystifying CytoSorbents: Insights From 4 Analyst Reviews
CTSOD. Boral Capital Maintains Buy on CytoSorbents, Maintains $10 Price Target
CTSOCytoSorbents Provides Regulatory Update For Its FDA-Designated Breakthrough Device, DrugSorb-ATR
CTSOCytoSorbents Received $1.7M In Cash Proceeds From The Sale Of Its 2023 And Amended 2022 Net Operating Loss And R&D Tax Credits From The Technology Business Tax Certificate Transfer Program, Sponsored By The New Jersey Economic Development Authority
CTSOHC Wainwright & Co. Reiterates Neutral on CytoSorbents, Maintains $1 Price Target
CTSOThe Analyst Verdict: CytoSorbents In The Eyes Of 4 Experts
CTSOD. Boral Capital Maintains Buy on CytoSorbents, Maintains $10 Price Target
CTSOCytoSorbents Q4 2024 Adj. EPS $(0.03) Beats $(0.06) Estimate, Sales $9.200M Miss $10.100M Estimate
CTSOInsights into CytoSorbents's Upcoming Earnings
CTSOCytoSorbents Continues To Reiterate Preliminary Expectations For Q4; Continues To Expect Regulatory Decisions On DrugSorb-ATR Marketing Applications In 2025
CTSOCytoSorbents Reschedules Q4 2024 Earnings Call To Allow More Time To Complete Annual Financial Audit
CTSOCytoSorbents Delays Earnings Release To Allow Additional Time Tor Annual Audit Completion After Corporate Controller's Passing
CTSOD. Boral Capital Maintains Buy on CytoSorbents, Maintains $10 Price Target
CTSOCytoSorbents Raises $1.6M With Exercise Of Previously Announced Series A Right Warrants
CTSOExpert Outlook: CytoSorbents Through The Eyes Of 7 Analysts
CTSOD. Boral Capital Maintains Buy on CytoSorbents, Maintains $10 Price Target
CTSOEF Hutton Maintains Buy on CytoSorbents, Maintains $10 Price Target
CTSOCytoSorbents Submits Health Canada Medical Device License Application f\For DrugSorb-ATR , Concurrent With MDSAP Certification Receipt
CTSOThe U.S. Department Of Defense Awards CytoSorbents An Approximately $2.0M Contract To Support HemoDefend-BGA Development
CTSOB. Riley Securities Maintains Buy on CytoSorbents, Lowers Price Target to $6
CTSOHC Wainwright & Co. Maintains Buy on CytoSorbents, Lowers Price Target to $9
CTSOCytoSorbents Q1 EPS $(0.21) Misses $(0.12) Estimate, Sales $8.69M Miss $9.73M Estimate
CTSORecap: CytoSorbents Q1 Earnings
CTSOCytoSorbents (NASDAQ:CTSO) reported its Q1 earnings results on Tuesday, May 3, 2022 at 04:15 PM.
Here's what investors need to know about the announcement.
Earnings
CytoSorbents missed estimated earnings by 75.0%, reporting an EPS of $-0.21 versus an estimate of $-0.12.
CytoSorbents Reports First Patient Enrolled In US Safe, Timely Antithrombotic Removal-Direct Oral Anticoagulants Trial Evaluating Its DrugSorb
CTSO